Skye Bioscience (SKYE) risk factors

77 risks, 5 new, 1 dropped, 18 reworded since the prior year. Severe going concern doubt driven by $55,924,814 in net losses for 2025 and only $25,737,221 in cash. Facing a Nasdaq delisting notice after 39 consecutive days under $1.00 per share. Hit with securities class action litigation and derivative lawsuits regarding nimacimab statements in late 2025 and early 2026.

73 risks. Skye Bioscience is entirely dependent on the clinical success and regulatory approval of its single product candidate, nimacimab. The company has a limited operating history, has incurred significant losses, and requires substantial additional financing. Operations are heavily exposed to complex manufacturing partnerships, intellectual property risks, and stringent FDA regulations governing biologic-device combination products.